← All trials
NCT05199324
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2022
- Primary completion
- Jan 1, 2025
- Completion date
- Mar 1, 2025
- First posted
- Jan 20, 2022
- Last posted
- Jul 1, 2022
- Enrollment
- 720
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Nanyang Technological UniversityLead sponsor
- Changi General HospitalCollaborator
- University of LondonCollaborator
- Melbourne HealthCollaborator
- Singapore Clinical Research InstituteCollaborator
- Singapore General HospitalCollaborator
- University of MalayaCollaborator
- University of QueenslandCollaborator
- National University of SingaporeCollaborator
- Rush UniversityCollaborator
- Nanyang Technological UniversityOverall official - principal investigator
- Sungkyunkwan UniversityCollaborator
- Ng Teng Fong General HospitalCollaborator
- Sengkang General HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.